Pharma BD Deal Intelligence

Perrigo Company plc / Elan Corporation plc

2013 · Acquisition/Merger · $8.6B · Complete

Announcement Sentiment

Neutral / mixed

Perrigo to acquire Elan in cash-and-stock deal valued ~$8.6B; tax inversion to Ireland. Elan shareholders received $6.25 cash + 0.07636 New Perrigo shares per Elan share.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Impaired/Written Down

Assessment window: 10yr post-close.

Key facts

Announced Jul 29, 2013
Closed Dec 18, 2013
Deal value $8.6B
Deal type Acquisition/Merger
Therapeutic area OTC, specialty (post-Tysabri divestment)
Indications OTC, specialty (post-Tysabri divestment)
Key assets Tysabri royalty stream (post-Biogen sale) plus Irish corporate domicile
Mechanism Anti-VLA-4 monoclonal antibody (Tysabri royalty); generic/store-brand OTC

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals